Cancer Family
Malignant Skin Neoplasm
CI-CAN-00000250Explore in graph →
320 active trials14 approved drugs64 evidence items
- NCIt
- C2920
Loading cancer entity…
Cancer Family
CI-CAN-00000250Explore in graph →
Clinical trials
1,248 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (202)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04929028 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT01787409 |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency |
| active not recruiting |
| N/A |
| 565 |
| Mayo ClinicOTHER |
| 1 |
| Jun 16, 2026 |
| clinicaltrials |
| NCT04068155 | Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors | recruiting | N/A | 80 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04305145 | Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis | active not recruiting | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04534127 | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia | recruiting | N/A | 56 | Alpha Tau Medical LTD.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648407 | Therapeutic Induction of Dermal Remodeling in Veterans to Prevent Actinic Neoplasia Caused by Chronic Environmental Exposure to Ultraviolet Radiation | not yet recruiting | N/A | 96 | VA Office of Research and DevelopmentFED | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03602157 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | active not recruiting | Phase 1 | 43 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04960618 | Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome | active not recruiting | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07266142 | Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker | recruiting | — | 7,500 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02910700 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | active not recruiting | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05076760 | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | recruiting | Phase 1 | 40 | Memgen, Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06567314 | Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma | recruiting | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07286318 | A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients | recruiting | Early Phase 1 | 20 | Marissa LoblOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07628894 | Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy | not yet recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06319196 | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma(ClearMe) | recruiting | Phase 2 | 54 | University Health Network, TorontoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma(DUET-MEL) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07624981 | Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions(DIAGNO-KA) | active not recruiting | — | 140 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03944941 | Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer | active not recruiting | Phase 2 | 60 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04315701 | A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer | active not recruiting | Phase 2 | 35 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06608511 | Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | active not recruiting | — | 20 | University of Wisconsin, MadisonOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07539454 | Nirogacestat in Patients With Kaposi Sarcoma | not yet recruiting | Phase 2 | 28 | AIDS Malignancy ConsortiumNETWORK | 1 | May 28, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT07422805 | Circulating Tumor DNA in Melanoma Patients(ctDNA) | active not recruiting | Phase 1 / Phase 2 | 176 | Institute of Oncology LjubljanaOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07608549 | FLASH Pilot Phase 1 Safety Study | not yet recruiting | N/A | 10 | Lesley A. JarvisOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06998342 | MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer(MOHSAHRTSS) | recruiting | Phase 2 | 24 | University of Vermont Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07606508 | Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.(CAREPI) | recruiting | — | 1,500 | University Hospital, LilleOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05186753 | (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | active not recruiting | Phase 2 | 237 | Cogent Biosciences, Inc.INDUSTRY | 15 | May 22, 2026 | clinicaltrials |
| NCT06489301 | Mechanisms for Laser-Induced Rejuvenation | recruiting | N/A | 12 | Wright State UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07330323 | CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients(CARES) | recruiting | N/A | 150 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02965716 | Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | active not recruiting | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | May 20, 2026 | clinicaltrials |
| NCT03491176 | Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer | active not recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06782399 | Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma(SCC) | enrolling by invitation | Early Phase 1 | 25 | Oliver JonasOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05574101 | A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer | active not recruiting | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03038672 | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas | active not recruiting | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | May 12, 2026 | clinicaltrials |
| NCT06992427 | High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer(HOPE) | recruiting | Phase 3 | 228 | Alliance for Clinical Trials in OncologyOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07455331 | Flash Radiotherapy for Skin Cancer(LANCE) | not yet recruiting | Phase 2 | 60 | Jules Bordet InstituteOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05747625 | (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma | recruiting | Phase 1 | 60 | Eben RosenthalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06384924 | Raman Spectroscopy and Skin Cancer | recruiting | — | 20 | Tiezhi ZhangOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03503240 | Patient Satisfaction With Appearance, Scar Outcome and Quality of Life After Skin Cancer Surgery | enrolling by invitation | — | 3,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07358637 | AI-enhanced OCT Imaging for Pre-surgical Margin Detection of Basal Cell Carcinoma | not yet recruiting | — | 30 | Henry Ford Health SystemOTHER | 0 | May 6, 2026 | clinicaltrials |
| NCT03713203 | PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).(PAGETEX) | recruiting | N/A | 24 | University Hospital, LilleOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04778449 | Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma | recruiting | — | 5,000 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 17, 2026source: clinicaltrials